



NYSE American: AGE

Master Investor Show 2019

April 6, 2019

Forward Looking Statements

The matters discussed in this presentation include forward looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the success of AgeX Therapeutics and its affiliates in developing new stem cell-based products and technologies; results of clinical trials of such products; the ability of AgeX and its licensees to obtain additional FDA and foreign regulatory approval to market products; competition from products manufactured and sold or being developed by other companies; the price of and demand for such products; the ability of AgeX and its subsidiaries to maintain patent and other intellectual property rights; and the ability of AgeX to raise the capital needed to finance its current and planned operations. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. As actual results may differ materially from the results anticipated in these forward-looking statements they should be evaluated together with the many uncertainties that affect the business of AgeX and its other subsidiaries, particularly those mentioned in the cautionary statements found in AgeX's Securities and Exchange Commission filings. AgeX disclaims any intent or obligation to update these forward-looking statements.


History of the Biotechnology Revolutions

Recombinant DNA Technology




- 1974 – Gene cloning technology developed
- 1976 - Moratorium on rDNA research initiated led to established guidelines on rDNA research
- 1989 – First \$B product EPO
- Today, products from the use of rDNA technology are ubiquitous
- >140 clinical trials
- Current Global Market \$75 B

Monoclonal Antibodies



- 1975 - Hybridoma technology developed
- 1997- First \$B Product Rituximab
- Advances in Mab Engineering
- Today, eight of the 20 best-selling biotechnology drugs in therapeutic monoclonal antibodies
- > 200 clinical trials
- Current Global Market \$44 B


Regenerative Medicine



- 1997 – Isolation of the immortalizing gene telomerase
- 1998 – First immortal Pluripotent Stem Cells (PSCs) isolated
- 2000/2010 – Reversal of mammalian/human cell aging
- Future – 1st \$B product


The Target Market

Aging and chronic degenerative disease




- 80% of \$2.5T health care costs associated with chronic disease.
- 80% of elderly have at least one chronic disease, 68% have two or more.

The Ideal Technology Platform



Young Cells

+




Matrix

=

Regenerative
Medicine
For Age-Related
Degenerative
Disease

Universal *PureStem*TM Technology



- >200-fold diversity
- Scalable, monoclonally-purified regenerative progenitor cell lines
- Off-the-shelf use

Value of the UniverCyte Pluripotent Platform

Classical biologics off-the-shelf business model

Traditional
Biologics



*Centralized
Production
Facility*



*Distributed
Frozen
Inventory*






Point Of Care

UniverCyte-
Derived
Cell Therapy
Products




AgeX-BAT1




AgeX-BAT1

West et al. Stem Cell Research & Therapy (2019) 10:7


AgeX-VASC1



AgeX-VASC1



New Young
Vasculature



Markets


- 30M Americans have diabetes¹ 1:3 Americans will have diabetes by 2050
- The global market for diabetes mellitus and obesity is set to rise from \$70.8 billion in 2015 to \$163.2 billion by 2022².
- Cardiovascular market >\$1 Trillion in U.S. by 2035³.

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States. US Department of Health and Human Services; Atlanta, GA: 2014.



2. GBI Research

3. http://www.heart.org/idc/groups/heart-public/@wcm/@adv/documents/downloadable/ucm_491543.pdf

Reprogramming of Human Cell Aging




Regen Med 2010 May;5(3):345-63



Reprogramming Methylation Age

A Data 77 $p = 1e-14$




Genome Biol. 2013;14(10):R115

Induced Telomerase & Regeneration (iTR™)

Embryonic



Fetal - Adult



Aging Adult



Highly Regenerative
Construction




Declining Regeneration
Maintenance



Non-Regenerative
Destruction

↑
Age Reversal through Telomerase
Activation & Induced Regeneration



Summary

- Largest challenge is chronic degenerative diseases of aging
- Large business opportunity: Young cells for aged tissues
- Proprietary manufacturing technology yielding:
 - Industrially-scalable product
 - Purity & identity
 - Off-the-shelf (allogeneic)
- iTR – Reversing the aging of cells *in vivo*